Lupin gets FDA nod to market generic antibiotic medicine in US
Doxycyline capsule is a generic equivalent of Galderma Laboratories' Oracea capsules
Lupin recently said it has received approval from the US health regulator to market Doxycycline capsules used to treat bacterial infections in the American market, Lupin said in a statement.
The drug firm has received tentative approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline capsules, 40 mg, a generic equivalent of Galderma Laboratories’ Oracea capsules, the statement added.
Edits by EP News Bureau